This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Atrialfibrillation is the most prevalent arrhythmia with a lifetime risk of nearly 30%. It can be associated with reduced quality of life and complications such as heartfailure and stroke. Pulmonary vein isolation (PVI) is the most effective treatment for rhythm control.
Radiofrequency ablation (RFA) is an important therapeutic modality for atrialfibrillation (AF), widely utilized in clinical practice due to its safety and significant efficacy. Head CT scans showed hypoattenuating areas indicative of cerebral infarction, chest CT suggested possible air accumulation in the left atrial region.
This systematic review and meta-analysis investigates the efficacy of catheter ablation compared with rate or rhythm control among patients with atrialfibrillation and heartfailure.
Atrialfibrillation (AFib) is a common heart rhythm disorder characterized by an irregular and often rapid heartbeat. This condition can lead to various complications, including stroke and heartfailure, making it essential to understand its causes, symptoms, and AFib treatment options. What is AtrialFibrillation?
(MedPage Today) -- The efficacy of catheter ablation for heartfailure (HF) patients with atrialfibrillation (Afib or AF) hinged on the phenotype of disease, researchers reported based on a meta-analysis. Compared with conventional rate or rhythm.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablateheart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S.
Patients who undergo catheter ablation for atrialfibrillation (AFib) who also have heartfailure with preserved ejection fraction (HFpEF) experienced a greater benefit from ablation in terms of clinical outcome, AFib recurrence and functional status, according to findings from the CABANA trial.
Introduction Catheter ablation is an effective and safe strategy for treating atrialfibrillation patients. Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. Among the catheter ablation group, 58.7% ( n = 27) had persistent atrialfibrillation.
Introduction A high recurrence rate of atrialfibrillation was monitored after catheter ablation for persistent atrialfibrillation. The results will evaluate sacubitril/valsartan as a novel treatment for improving prognosis and a complement to conventional drug therapy.
Patients with heartfailure (HF) and atrialfibrillation (AF) frequently undergo catheter ablation to maintain sinus rhythm and improve cardiovascular outcomes.
Atrialfibrillation catheter ablation (AFCA) improved clinical outcomes compared with medical treatment alone, and early AFCA was associated with better outcomes than late AFCA, particularly decreased risk of heartfailure (HF) hospitalization and atrialfibrillation (AFib) recurrence.
AtrialFibrillation (AF) and HeartFailure (HF) are closely interlinked. Pulsed Field Ablation (PFA) has been demonstrated to promote fast and durable Pulmonary Vein Isolation (PVI) without the risk of PV stenosis or damage to adjacent structures.
The concept of a 3-month blanking period after catheter ablation (CA) for atrialfibrillation (AF) is widely accepted. However, in AF patients with heartfailure (HF), EPR might adversely affect outcomes, though the details remain unclear.
Rhythm control is an important strategy in managing atrialfibrillation (AF) in patients with heartfailure (HF). However, data on the long-term efficacy of catheter ablation for AF in HF remains scarce.
Catheter Ablation for AtrialFibrillation (AFib) in heartfailure is now a class I indication for patients with heartfailure. Evidence supports the relationship between obesity and the incidence and recurrence of Afib.
Clinical outcomes among patients with atrialfibrillation (AF) and heartfailure with preserved ejection fraction (HFpEF) treated with catheter ablation (CA) versus antiarrhythmic therapy (AAT) are not well-known.
Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation 5. Henry Ford Health HeartFailure Patient First in Michigan to Receive Breakthrough Device 6. Machine Learning Informs a New Tool to Guide Treatment for Acute Decompensated HeartFailure 8.
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: HeartFailure Reveals that Despite Significant Efforts to Improve Acute HeartFailure Treatment Over the Past 20 Years, Management Remains Unchanged 3.
Atrialfibrillation (AF) is a common reversible cause of worsening left ventricular ejection fraction (LVEF) in patients with heartfailure. Guidelines propose a class 1 recommendation for AF catheter ablation (CA) in patients with heartfailure with reduced ejection fraction1,2.
Studies have shown detrimental effects of atrialfibrillation (AF) occurrence among patients with heartfailure (HF) with a preserved ejection fraction (HFpEF). Ablative therapy may counter this risk, but the impact of timing of ablation in paroxysmal vs. persistent AF is unclear.
Atrialfibrillation (AF) is a common arrhythmia in patients with heartfailure (HF). Catheter ablation of AF has been proven to be an effective therapeutic option for AF management in HF, particularly in heartfailure with reduced ejection fraction (HFrEF) [2, 3].
The efficacy of catheter ablation as a treatment approach for patients with concurrent atrialfibrillation (AF) and heartfailure with preserved ejection fraction (HFpEF) has been inadequately investigated.
Abstract A vast amount of now well-established clinical and epidemiological data indicates a close, interdependent, and symbiotic association between atrialfibrillation (AF) and heartfailure (HF). whether ablation is mandatory or pointless in patients who have HF).
Catheter ablation of atrialfibrillation (AF) is the preferred strategy for improving survival and reducing heartfailure (HF) hospitalizations in patients with heartfailure with reduced ejection fraction (HFrEF) and AF.
Overview of the study population and effects observed after catheter ablation for atrialfibrillation. Herein we describe the effects of catheter ablation on AF burden, arrhythmia recurrences, and ventricular function in end-stage HF. to 39.18.3% ( p <0.001) following ablation. PVI, pulmonary vein isolation.
The impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on atrialfibrillation (AF) recurrence outcomes and adverse cardiovascular outcomes in heartfailure (HF) patients after AF ablation is unknown.
Roughly half of patients with heartfailure (HF) have preserved ejection fraction (HFpEF). HFpEF and atrialfibrillation (AF) often coexist and share similar risk factors.
Studies have suggested that early atrialfibrillation (AF) ablation is associated with improved outcomes. However, it is unknown whether these patterns hold for persistent AF among patients with heartfailure with preserved ejection fraction (HFpEF). The majority of these studies evaluated paroxysmal AF cases.
The authors claim that their score identifies heartfailure (HF) patients who benefit the most from atrialfibrillation (AF) ablation. in favour of ablation in the “high-risk group” and 0.41 However, the crude hazard ratio (HR) for the primary endpoint was 0.32 in the “low-risk group”.
Previous studies have demonstrated significant morbidity and mortality in patients with heartfailure (HF) with reduced ejection fraction (HFrEF), particularly with accompanying atrialfibrillation (AF).
Medtronic Creates History with FDA Approval of its Novel PulseSelect Pulsed Field Ablation System to Treat AtrialFibrillation 3. AtrialFibrillation Market Reaches $20.92B, According to New Report 9. Patients Implanted with Innovative FIRE1 Remote HeartFailure Monitoring System in Early Feasibility Study
While there are several reports on the efficacy of catheter ablation for atrialfibrillation (AF) in patients with heartfailure with preserved ejection fraction (HFpEF), comprehensive data on the optimal catheter ablation strategy remain scarce.
The benefit of catheter ablation in patients with atrialfibrillation (AF) for patients with heartfailure with preserved ejection fraction (HFpEF) remains uncertain.
Left atrial and pulmonary artery pressure (PAP) elevation can reflect severity and dynamic status of heartfailure (HF) in HF with preserved ejection fraction (pEF). Atrialfibrillation (AF) worsens HFpEF progression and pump failure, but catheter ablation can restore rhythm control in this population.
To fully understand the predictive value of the CASTLE-HTx risk-score in relation to the benefits of catheter ablation in patients with end-stage heartfailure (HF) and atrialfibrillation (AF), it is essential to distinguish between absolute and relative risk reduction. 100 patient years)1.
Catheter ablation (CA) of atrialfibrillation (AF) has been proved to benefit patient with symptomatic AF and heartfailure. However, the data on neurological outcomes including cerebrovascular disease (CVA) and dementia remain a controversy.
Respiratory diseases are involved in the development and exacerbation of arrhythmias and heartfailure (HF). However, the impact of respiratory function on the recurrence and cardiovascular event during long-term follow up after catheter ablation of atrialfibrillation (AF) are not fully understood.
Atrialfibrillation (AF) is a prevalent arrhythmia associated with an increased risk of stroke, heartfailure, and overall morbidity. Catheter ablation is a cornerstone therapy for AF, aiming to isolate aberrant electrical signals in the left atrium (LA) and restore sinus rhythm.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content